The utilisation of long-acting insulin analogues and intermediate-acting insulin in patients with type 2 diabetes in the United Kingdom

被引：0
|
作者：
Brunetti, V. C. [1 ,2 ]
Yu, O. H. Y. [2 ,3 ]
Platt, R. W. [1 ,4 ]
Filion, K. B. [1 ,5 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ, Canada
[3] Jewish Gen Hosp, Div Endocrinol & Metab, Montreal, PQ, Canada
[4] McGill Univ, Dept Pediat, Montreal, PQ, Canada
[5] McGill Univ, Dept Med, Montreal, PQ, Canada
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
290
引用
收藏
页码：S146 / S146
页数：1
相关论文
共 50 条
  • [21] Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis.
    Tricco A.C.
    Ashoor H.M.
    Soobiah C.
    Hemmelgarn B.
    Moher D.
    Hutton B.
    Yu C.H.
    Majumdar S.R.
    Straus S.E.
    [J]. Systematic Reviews, 2 (1) : 73
  • [22] Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products
    Bullano, MF
    Al-Zakwani, I
    Barron, JJ
    Menditto, L
    Willey, VJ
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 340 - 340
  • [23] PHARMAC responds on long-acting insulin analogues
    Metcalfe, Scott
    Evans, Jackie
    Moodie, Peter
    [J]. NEW ZEALAND MEDICAL JOURNAL, 2005, 118 (1224) : 99 - 107
  • [24] Are long-acting insulin analogues better than isophane insulin?
    Schooff, Michael D.
    Gupta, Lalita
    [J]. AMERICAN FAMILY PHYSICIAN, 2008, 77 (04) : 447 - 449
  • [25] Intermediate acting versus long acting insulin for type 1 diabetes mellitus
    Vardi, Moshe
    Jacobson, Eyal
    Nini, Asaph
    Bitterman, Haim
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (03):
  • [26] Insulin therapy in type 2 diabetes:: role of the long-acting insulin glargine analogue
    Yki-Järvinen, H
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) : 410 - 416
  • [27] Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products
    Bullano, MF
    Al-Zakwani, IS
    Fisher, MD
    Menditto, L
    Willey, VJ
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (02) : 291 - 298
  • [28] Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
    Chang, Chia-Hsuin
    Chuang, Lee-Ming
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2018, 9 (04): : 728 - 730
  • [29] Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years
    Lee, Tsung-Ying
    Kuo, Shihchen
    Yang, Chen-Yi
    Ou, Huang-Tz
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (05) : 852 - 860
  • [30] (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
    Hemmingsen, Bianca
    Metzendorf, Maria-Inti
    Richter, Bernd
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03):
12345